Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 5/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 5/20 | 0.47 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3263621 | 0.84 | SLC5A1 (0.50) | SLC5A1SLC5A2MEN1LMNAKMT2A | |
| SCHEMBL17156289 | 0.81 | SLC5A1 (0.46) | SLC5A1SLC5A2IKBKEHTR2CHTR2B | |
| SCHEMBL12243923 | 0.78 | SLC5A1 (0.52) | SLC5A1SLC5A2ARMEN1LMNA | |
| SCHEMBL16475989 | 0.75 | IKBKE (0.53) | IKBKEL3MBTL1MEN1LMNAKMT2A | |
| SCHEMBL3262752 | 0.74 | SLC5A2 (0.49) | SLC5A1SLC5A2ARMEN1LMNA | |
| SCHEMBL7512103 | 0.72 | SMN1; SMN2 (0.62) | L3MBTL1MEN1LMNAKMT2AMAPT | |
| SCHEMBL4858748 | 0.72 | DAPK1 (0.40) | SLC5A1SLC5A2L3MBTL1HTR2CCNR1 | |
| SCHEMBL4854533 | 0.71 | TP53 (0.42) | L3MBTL1HTR2CLMNAKMT2AMAPT | |
| SCHEMBL1774454 | 0.71 | LMNA (0.66) | ARMEN1LMNAKMT2AMAPT | |
| SCHEMBL7506593 | 0.70 | PPARG (0.48) | IKBKEL3MBTL1HTR2CHTR2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439232-B2 | Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-10-21 | — | — | US | disclosed |
| US-20060194809-A1 | Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1609799-A1 | HETEROARYL 5-THIO-BETA-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2005-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194809-A1 | Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same | SLC5A2, SLC5A1, UGGT1 | SLC5A1 2/4885SLC5A2 1/4885IKBKE 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.